Farallon Capital Management LLC Fate Therapeutics Inc Transaction History

Farallon Capital Management LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $21.5 Million - $43.7 Million	-725,525 Reduced 95.79%	31,900 $1.24 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $74.3 Million - $100 Million	-1,553,973 Reduced 67.23%	757,425 $44.3 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $24.1 Million - $38.9 Million	406,398 Added 21.33%	2,311,398 $137 Million
Q2 2021 Aug 13, 2021	BUY	$67.25 - $92.52 $336,250 - $462,600	5,000 Added 0.26%	1,905,000 $165 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $79.4 Million - $129 Million	-1,100,000 Reduced 36.67%	1,900,000 $157 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $4.76 Million - $12.6 Million	-125,000 Reduced 4.0%	3,000,000 $273 Million
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $11.4 Million - $15.2 Million	-375,000 Reduced 10.71%	3,125,000 $125 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $10.1 Million - $17.6 Million	500,000 Added 16.67%	3,500,000 $120 Million
Q1 2020 May 15, 2020	BUY	$17.28 - $31.88 $13 Million - $23.9 Million	750,000 Added 33.33%	3,000,000 $66.6 Million
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $3.87 Million - $5.63 Million	-250,000 Reduced 10.0%	2,250,000 $34.9 Million
Q1 2019 May 15, 2019	BUY	$13.15 - $18.71 $3.95 Million - $5.61 Million	300,000 Added 13.64%	2,500,000 $43.9 Million
Q4 2018 Feb 14, 2019	BUY	$11.48 - $16.98 $19.2 Million - $28.4 Million	1,670,000 Added 315.09%	2,200,000 $28.2 Million
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $4.64 Million - $8.63 Million	530,000 New	530,000 $8.63 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Farallon Capital Management LLC with notifications on news.